GB202219507D0 - Use of pyridoxal in preparation of drugs for treating ovarian cancer - Google Patents
Use of pyridoxal in preparation of drugs for treating ovarian cancerInfo
- Publication number
- GB202219507D0 GB202219507D0 GBGB2219507.7A GB202219507A GB202219507D0 GB 202219507 D0 GB202219507 D0 GB 202219507D0 GB 202219507 A GB202219507 A GB 202219507A GB 202219507 D0 GB202219507 D0 GB 202219507D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pyridoxal
- drugs
- preparation
- ovarian cancer
- treating ovarian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011577585.5A CN112691103B (en) | 2020-12-28 | 2020-12-28 | Application of pyridoxal in preparation of medicine for treating ovarian cancer |
| PCT/CN2021/135415 WO2022143010A1 (en) | 2020-12-28 | 2021-12-03 | Use of pyridoxal in preparation of drugs for treating ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202219507D0 true GB202219507D0 (en) | 2023-02-08 |
| GB2611905A GB2611905A (en) | 2023-04-19 |
Family
ID=75512203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2219507.7A Pending GB2611905A (en) | 2020-12-28 | 2021-12-03 | Use of pyridoxal in preparation of drugs for treating ovarian cancer |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN112691103B (en) |
| GB (1) | GB2611905A (en) |
| WO (1) | WO2022143010A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112691103B (en) * | 2020-12-28 | 2022-07-26 | 重庆医科大学附属第一医院 | Application of pyridoxal in preparation of medicine for treating ovarian cancer |
| CN115531380A (en) * | 2022-09-19 | 2022-12-30 | 重庆医科大学附属第一医院 | Application of fluoropyridoxine in preparation of anti-cancer drugs |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1537532A (en) * | 2003-04-18 | 2004-10-20 | 方 谢 | Pyridoxin and application of its derivatives in preparation of medicine |
| CA2789249A1 (en) * | 2010-02-19 | 2011-08-25 | Long Mao | Heterocyclic compounds and uses as anticancer agents |
| CN104922697B (en) * | 2015-05-26 | 2018-02-27 | 复旦大学附属金山医院 | Reduce pyridoxine phosphate oxidation enzyme treatment oophoroma |
| CN106727620B (en) * | 2016-12-01 | 2020-03-31 | 复旦大学附属金山医院 | Application of pyridoxal phosphate in preparation of medicine for treating ovarian cancer |
| CN112691103B (en) * | 2020-12-28 | 2022-07-26 | 重庆医科大学附属第一医院 | Application of pyridoxal in preparation of medicine for treating ovarian cancer |
-
2020
- 2020-12-28 CN CN202011577585.5A patent/CN112691103B/en active Active
-
2021
- 2021-12-03 WO PCT/CN2021/135415 patent/WO2022143010A1/en active Application Filing
- 2021-12-03 GB GB2219507.7A patent/GB2611905A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112691103B (en) | 2022-07-26 |
| WO2022143010A1 (en) | 2022-07-07 |
| CN112691103A (en) | 2021-04-23 |
| GB2611905A (en) | 2023-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202219507D0 (en) | Use of pyridoxal in preparation of drugs for treating ovarian cancer | |
| EP3524268A4 (en) | Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers | |
| IL261195B (en) | Combination therapy for treatment of ovarian cancer | |
| EP3566710A4 (en) | Therapeutic agent and application thereof in drugs for treating tumors and/or cancer | |
| IL289787A (en) | Antibody combinations for treatment of cancer in specific patients | |
| EP4066842A4 (en) | Application of car t-cells in preparing drug for treating cancer | |
| EP4149547A4 (en) | Compositions and methods for treating cancer | |
| IL288086A (en) | Methods and materials for treating cancer | |
| EP3464591A4 (en) | A composition and method of using mir-302 precursors as anti-cancer drugs for treating human lung cancer | |
| EP3498274C0 (en) | Application of phosphodiesterase 4 inhibitor zl-n-91 in preparation of medicament for treating prostate cancer proliferation and metastasis | |
| IL280830A (en) | Conjugates for use in methods of treating cancer | |
| IL304467A (en) | Pharmaceutical compositions for treating breast cancers and methods of uses thereof | |
| IL274008A (en) | Anti-msln antibody and pharmaceutical composition comprising same for cancer treatment | |
| EP3295949A4 (en) | Topical drug for treating breast cancer and preparation method thereof | |
| GB201610910D0 (en) | Composition and apparatus for treatment of chemotherapy induced alopecia | |
| IL312846A (en) | Methods and compositions for treating cancer | |
| IL312844A (en) | Methods and compositions for treating cancer | |
| IL309120A (en) | Methods and compositions for treating cancer | |
| IL309071A (en) | Methods and compositions for treating cancer | |
| EP3501539A4 (en) | Application of anti-pl2l60 protein antibody in preparing anti-tumor drug and method for treating tumors | |
| EP4209216A4 (en) | Pharmaceutical composition for treating tumors | |
| EP4237090A4 (en) | Methods for the detection and treatment of ovarian cancer | |
| EP4174087A4 (en) | Drug for treating tumor | |
| IL288178A (en) | Gmci and ddri combination therapy for treating cancer | |
| EP4093386A4 (en) | Dosing regimens and methods for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 789A | Request for publication of translation (sect. 89(a)/1977) |
Ref document number: 2022143010 Country of ref document: WO |